학술논문
SWITCH TO DOR/ISL (100/0.75MG) QD: WEEK 48 RESULTS FROM AN OPEN-LABEL PHASE 3 TRIAL.
Document Type
Article
Author
Source
Topics in Antiviral Medicine; Apr2023, Vol. 31 Issue 2, p80-81, 2p
Subject
Language
ISSN
21615861